These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

234 related articles for article (PubMed ID: 35032444)

  • 61. How do we know if an exposure is actually teratogenic in humans?
    Friedman JM
    Am J Med Genet C Semin Med Genet; 2011 Aug; 157C(3):170-4. PubMed ID: 21766430
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Calls to a teratogen information service regarding potential exposures in pregnancy and breastfeeding.
    Campbell SC; Kast TT; Kamyar M; Robertson J; Sherwin CM
    BMC Pharmacol Toxicol; 2016 Jul; 17(1):33. PubMed ID: 27449139
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Ethical challenges of pregnancy prevention programs.
    Bonebrake R; Casey MJ; Huerter C; Ngo B; O'Brien R; Rendell M
    Cutis; 2008 Jun; 81(6):494-500. PubMed ID: 18666392
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Perception of pregnant Japanese women regarding the teratogenic risk of medication exposure during pregnancy and the effect of counseling through the Japan drug information institute in pregnancy.
    Yakuwa N; Nakajima K; Koinuma S; Goto M; Suzuki T; Ito N; Watanabe O; Murashima A
    Reprod Toxicol; 2018 Aug; 79():66-71. PubMed ID: 29885359
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Dose-dependent risk of malformations with antiepileptic drugs: an analysis of data from the EURAP epilepsy and pregnancy registry.
    Tomson T; Battino D; Bonizzoni E; Craig J; Lindhout D; Sabers A; Perucca E; Vajda F;
    Lancet Neurol; 2011 Jul; 10(7):609-17. PubMed ID: 21652013
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Birth defects after prenatal exposure to antiepileptic drugs.
    Perucca E
    Lancet Neurol; 2005 Nov; 4(11):781-6. PubMed ID: 16239185
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Teratogenic risk with etretinate and acitretin treatment.
    Geiger JM; Baudin M; Saurat JH
    Dermatology; 1994; 189(2):109-16. PubMed ID: 8075435
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Identifying associations between maternal medication use and birth defects using a case-population approach: an exploratory study on signal detection.
    de Jonge L; Zetstra-van der Woude PA; Bos HJ; de Jong-van den Berg LT; Bakker MK
    Drug Saf; 2013 Nov; 36(11):1069-78. PubMed ID: 23828658
    [TBL] [Abstract][Full Text] [Related]  

  • 69. The outcomes of pregnancy in women exposed to the new macrolides in the first trimester: a prospective, multicentre, observational study.
    Bar-Oz B; Weber-Schoendorfer C; Berlin M; Clementi M; Di Gianantonio E; de Vries L; De Santis M; Merlob P; Stahl B; Eleftheriou G; Maňáková E; Hubičková-Heringová L; Youngster I; Berkovitch M
    Drug Saf; 2012 Jul; 35(7):589-98. PubMed ID: 22702640
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Unintended pregnancies and exposure to potential human teratogens.
    Han JY; Nava-Ocampo AA; Koren G
    Birth Defects Res A Clin Mol Teratol; 2005 Apr; 73(4):245-8. PubMed ID: 15786494
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Improving the Safety of Teratogen Prescribing Practices in a Pediatric Rheumatology Clinic.
    Cooper AM; Horwitz M; Becker ML
    Pediatrics; 2019 Apr; 143(4):. PubMed ID: 30837294
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Risk management of teratogenic medicines: A systematic review.
    Shroukh WA; Steinke DT; Willis SC
    Birth Defects Res; 2020 Dec; 112(20):1755-1786. PubMed ID: 32918401
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Knowledge transfer and translation: examining how teratogen information is disseminated.
    Shahin I; Einarson A
    Birth Defects Res A Clin Mol Teratol; 2011 Nov; 91(11):956-61. PubMed ID: 21948595
    [TBL] [Abstract][Full Text] [Related]  

  • 74. A comparative review of the isotretinoin pregnancy risk management programs across four continents.
    Kovitwanichkanont T; Driscoll T
    Int J Dermatol; 2018 Sep; 57(9):1035-1046. PubMed ID: 29508918
    [TBL] [Abstract][Full Text] [Related]  

  • 75. First-trimester itraconazole exposure and pregnancy outcome: a prospective cohort study of women contacting teratology information services in Italy.
    De Santis M; Di Gianantonio E; Cesari E; Ambrosini G; Straface G; Clementi M
    Drug Saf; 2009; 32(3):239-44. PubMed ID: 19338381
    [TBL] [Abstract][Full Text] [Related]  

  • 76. The CTIS Womb to Classroom Screening Program for the detection of agents with adverse effects on neuropsychological development.
    Adams J; Janulewicz PA; Kao K; Jones KL; Chambers C
    Birth Defects Res A Clin Mol Teratol; 2012 Jun; 94(6):486-93. PubMed ID: 22522347
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Assessing the availability of the teratogenic drug isotretinoin outside the pregnancy prevention programme: a survey of e-pharmacies.
    Lagan BM; Dolk H; White B; Uges DR; Sinclair M
    Pharmacoepidemiol Drug Saf; 2014 Apr; 23(4):411-8. PubMed ID: 24493556
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Birth outcomes following zidovudine exposure in pregnant women: the Antiretroviral Pregnancy Registry.
    White A; Eldridge R; Andrews E
    Acta Paediatr Suppl; 1997 Jun; 421():86-8. PubMed ID: 9240865
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Human teratogens: update 2010.
    Holmes LB
    Birth Defects Res A Clin Mol Teratol; 2011 Jan; 91(1):1-7. PubMed ID: 21254353
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Teratogenesis associated with antibipolar agents.
    Nguyen HT; Sharma V; McIntyre RS
    Adv Ther; 2009 Mar; 26(3):281-94. PubMed ID: 19330496
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.